There's a certain irony in flooding a surgical field with fluorescent dye to see if tissue is healthy enough. Hypervision Surgical, a London-based spinout from King's College, thinks there's a better way: skip the dye entirely and let hyperspectral imaging do the work.
The company just closed a £17 million Series A round, announced April 29, 2026, led by German healthtech investor Heal Capital. It's an oversubscribed financing that drew an eclectic mix of backers—venture funds, a cancer charity, even the investment arm of a major surgical society. That breadth suggests the technology has caught attention across corners of the healthcare world that don't often overlap.
Hypervision's pitch is straightforward, if technically ambitious. Its platform uses hyperspectral imaging combined with artificial intelligence to measure tissue oxygen saturation in real time during surgery. Surgeons see perfusion data overlaid on their video feed—color-coded maps of tissue health updating at video frame rates. No indocyanine green, the fluorescent contrast agent that's become standard issue in many operating rooms. Just light, sensors, and algorithms.
Whether that proves compelling enough to displace an established technology remains an open question. But the early signals—regulatory clearances on both sides of the Atlantic, a notable board, and over 150 procedures logged by late last year—suggest the company has moved past purely theoretical promise.
An Unusual Coalition of Believers
The investor lineup reads like a cross-section of European healthtech. Heal Capital led, bringing in new backers Angelini Ventures, IP Group, and Daycrest. Four existing investors doubled down: HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures, all of whom participated in Hypervision's £6.5 million seed round on June 29, 2023.
Then there are the strategic additions. The SAGES Ingenuity SINC Fund—venture capital from the Society of American Gastrointestinal and Endoscopic Surgeons—came in, as did Macmillan Cancer Support, the UK charity increasingly active in impact investing. It's not every day a cancer nonprofit writes checks alongside traditional VCs, but surgical outcomes in oncology cases make the thesis clear enough.
Rick Mangat joined the board alongside the financing. He founded Novadaq, the fluorescence imaging company Stryker eventually acquired, which gives him a front-row understanding of both the market opportunity and the incumbents Hypervision is challenging. Martin Frost, who founded and led surgical robotics firm CMR Surgical, already chairs the board—he came aboard during the seed round. It's the kind of bench you'd want if you're planning to elbow into an operating room dominated by much larger players.
The Technology: Light Instead of Liquid
Hyperspectral imaging isn't new—it's been used in everything from agriculture to military reconnaissance. Applying it to surgery in real time, though, required solving latency and processing problems that older systems couldn't handle. Hypervision built its first product, the HyperSnap Surgical System, on NVIDIA's IGX platform, a medical-grade edge AI system designed for the operating room's particular demands.
The device quantifies tissue oxygen saturation (StO₂) during both open and minimally invasive procedures. Instead of injecting dye and watching it flow, surgeons get continuous, objective measurements of tissue perfusion. The company targets general surgery initially, with a particular focus on colorectal procedures—an area where surgical failures can be both common and expensive.
Anastomotic leaks, where surgical connections in the bowel fail to heal, occur in up to 15% of colorectal cases, according to Hypervision's figures. Each complication can cost north of $50,000 to manage. If real-time perfusion data could even modestly reduce those rates, the health economics start to look compelling. Of course, that's the promise. The clinical evidence will need to follow.
The company is co-developing next-generation spectral sensors with imec, the Belgian nanoelectronics research hub, under a strategic partnership announced on August 12, 2025. That collaboration suggests Hypervision is thinking beyond its first-generation hardware—an important signal given how quickly sensor technology tends to evolve.
Regulatory Milestones and Early Use
Hypervision secured FDA 510(k) clearance for HyperSnap on June 24, 2025, classifying it as a Class II device for use as an adjunctive monitor of superficial StO₂ for open and minimally invasive general surgery using compatible telescopes. The company also obtained UKCA marking for the UK market in December 2024, positioning it to operate on both sides of the Atlantic.
The FDA had previously accepted HyperSnap into its Safer Technologies Program (STeP) on April 14, 2024—a designation reserved for devices addressing unmet medical needs with potential to meaningfully improve safety or effectiveness. It's not a guarantee of clinical success, but it does indicate the agency saw merit in the approach.
By November 2025, Hypervision reported over 150 procedures performed in UK operating rooms using its platform. A porcine study published last year demonstrated real-time laparoscopic hyperspectral imaging around colorectal anastomoses, showing the system could track perfusion changes as they happened. The company has presented early clinical data from human cases at surgical conferences, including abstracts accepted at the SAGES Annual Meeting, though peer-reviewed outcomes data in larger patient cohorts will ultimately determine whether adoption scales.
What Happens Next
Hypervision plans to use the Series A capital to accelerate commercial deployment, expand clinical adoption, and advance its sensor development work with imec. The company hasn't disclosed launch timelines or pricing—always a delicate dance in medical devices, where reimbursement pathways and hospital purchasing committees complicate straightforward go-to-market strategies.
The broader market for hyperspectral imaging systems is projected to hit $1.83 billion by 2030, according to a market research report from March, though that figure spans applications well beyond surgery. Still, it offers a sense of scale.
Hypervision enters a surgical imaging landscape long dominated by fluorescence-guided systems. Stryker, which acquired Novadaq, and Intuitive Surgical, whose da Vinci robots feature the Firefly NIR-ICG system, have built significant installed bases. The clinical evidence for ICG's impact on outcomes remains somewhat mixed, according to a 2025 systematic review and meta-analysis published by SAGES. That leaves an opening—perhaps a narrow one—for alternative approaches to prove their value.
Whether dye-free spectral imaging becomes the new standard or remains a niche tool will depend on clinical data, ease of use, and the always-unpredictable dynamics of surgeon adoption. For now, Hypervision has capital, regulatory clearance, and a hypothesis that the operating room is ready for something different.
Sometimes that's enough. Sometimes it isn't. The next chapter will be written in actual surgical suites, one procedure at a time.
